DNTH — Dianthus Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $4.45bn
- $4.04bn
- $2.04m
Annual income statement for Dianthus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 2.83 | 6.24 | 2.04 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 74.7 | 80.9 | 51 | 108 | 180 |
| Operating Profit | -74.7 | -80.9 | -48.2 | -102 | -178 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -71.1 | -76.5 | -43.6 | -85 | -162 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -71.1 | -76.5 | -43.6 | -85 | -162 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -71.1 | -76.5 | -43.6 | -85 | -162 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -71.1 | -76.5 | -43.6 | -85 | -162 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -20.7 | -20.6 | -8.45 | -2.55 | -4.2 |